Nesiritide: Research Status and Trial Data

Regulatory status

Nesiritide is classified as unapproved research material. There is no approved drug label on file for this compound, so no indications, dosing, or official safety information can be cited here.

What nesiritide is

Nesiritide is a peptide compound with the molecular formula C143H244N50O42S4 and a molecular weight of approximately 3,464. Its structure is a large, cyclic peptide chain built from a sequence of amino acids linked through peptide and disulfide bonds. It is catalogued under PubChem CID 71308561. Because no approved label exists, there is no FDA-sanctioned description of its mechanism or clinical use available for this summary.

Trial footprint

A total of 1,889 trials are registered that reference this compound. Among the sample of studies available, one phase 1 trial is examining whole heart radiotherapy for end-stage heart failure and is enrolling by invitation. A phase 3 trial looking at furosemide withdrawal in stable chronic heart failure outpatients has an unknown status. A further study without an assigned phase, part of a statins sub-study in elderly patients, is active but not recruiting. These listings reflect registration activity and status only, not outcomes or conclusions about effectiveness.